| 26.12 0.21 (0.81%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 32.56 | 1-year : | 38.03 |
| Resists | First : | 27.87 | Second : | 32.56 |
| Pivot price | 22.43  |
|||
| Supports | First : | 21.39 | Second : | 17.37 |
| MAs | MA(5) : | 24.98 |
MA(20) : | 21.5 |
| MA(100) : | 19.54 |
MA(250) : | 18.33 |
|
| MACD | MACD : | 1.6 |
Signal : | 1 |
| %K %D | K(14,3) : | 76.5 |
D(3) : | 77.3 |
| RSI | RSI(14): 74.6 |
|||
| 52-week | High : | 27.87 | Low : | 14.11 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ KNSA ] has closed below upper band by 7.3%. Bollinger Bands are 215% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 11 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 26.54 - 26.64 | 26.64 - 26.72 |
| Low: | 24.97 - 25.09 | 25.09 - 25.19 |
| Close: | 25.93 - 26.13 | 26.13 - 26.28 |
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.
Fri, 26 Jul 2024
Q3 2024 EPS Estimates for Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Raised by Wedbush - MarketBeat
Fri, 26 Jul 2024
Kiniksa Pharmaceuticals, Ltd. (KNSA) Is Up 0.09% in One Week: What You Should Know - Yahoo Finance
Fri, 26 Jul 2024
Recent Price Trend in Kiniksa Pharmaceuticals (KNSA) is Your Friend, Here's Why - Yahoo Finance
Fri, 26 Jul 2024
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Expected to Earn Q3 2024 Earnings of $0.06 Per Share - Defense World
Fri, 26 Jul 2024
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CEO Sanj K. Patel Sells 136,124 Shares of Stock - Defense World
Wed, 24 Jul 2024
Kiniksa Pharmaceuticals International And Two More Firms Possibly Priced Below Market Value Estimates - Simply Wall St
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 40 (M) |
| Shares Float | 14 (M) |
| Held by Insiders | 4.2 (%) |
| Held by Institutions | 98.8 (%) |
| Shares Short | 4,560 (K) |
| Shares Short P.Month | 4,120 (K) |
| EPS | 0.12 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.09 |
| Profit Margin | 2.8 % |
| Operating Margin | -20.8 % |
| Return on Assets (ttm) | -4 % |
| Return on Equity (ttm) | 2.1 % |
| Qtrly Rev. Growth | 65.1 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 7.46 |
| EBITDA (p.s.) | -0.71 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 22 (M) |
| Levered Free Cash Flow | 27 (M) |
| PE Ratio | 200.92 |
| PEG Ratio | 1.3 |
| Price to Book value | 4.28 |
| Price to Sales | 3.5 |
| Price to Cash Flow | 49.02 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|